PARP inhibitor biomarkers, such as olaparib for patients with BRCA1/2-mutant tumors, ovarian, and colorectal cancers; iniparib for breast and lung cancers; rucaparib for breast and ovarian cancer; and veliparib for melanoma and breast cancer, are used. Here, BRCA1 is linked to ovarian carcinoma.